Published 2010 | Version v1

Publication Metadata-only

A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.

Creators: ROSSO, RAFFAELLA; VISCOLI, CLAUDIO; Parodi A; Torrisi C; De Terlizzi F; Vignolo M.

Others:: Rosso, Raffaella; Parodi, A; Torrisi, C; De Terlizzi, F; Viscoli, Claudio; Vignolo, M.

Additional details

Created:: April 14, 2023
Modified:: November 28, 2023